Scancell Share Discussion Threads

[j777j] 06/4/2023 08:38

Year end tax selling over


Back up to the 20's

[ruckrover] 06/4/2023 08:18

Well I'm glad I'm not the only one who finds the endless tedium of what OTHER companies are doing slightly depressing.Isn't it bad enough having invested significant funds that have stagnated over 12 years without rubbing it in?

[panama7] 06/4/2023 08:05

Marcus, all you are doing by posting all these links regarding other Companies deals is confirming that Scancell are always the Bridesmaid and never the Bride, after 12 years still no Groom on the horizon.

[marcusl2] 05/4/2023 21:33

Across each of these malignancies, bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies were among the most exciting treatments to reach the market in 2022.

[the real lozan] 05/4/2023 13:39

Mawns lowed -
Time to relax / sleep
Bit like the trHYPE crew

[the real lozan] 04/4/2023 12:12

What a 'peach' of a day -
Clear blue skies, a mere 20 C in the sun south facing terrace
0 C expected in the night
Everything in blossom
Orchids (various) about to flower in our grassland
Pair of Sparrowhawks visiting every day hunting the flock of Sparrows that hide/reside in our stackof cut branches
Ordered our Oak log firewood for next winter this A M
Delivery Sept,,,,Still have plenty 'chez nous' to go at
Apparently, according to M Bruno (our log man0 everyone wants Oak logs now
Hense, he has taken on extra staff to deal with the demand
.
Life is good
Don't waste it

[j777j] 04/4/2023 10:41

Looks like the end of year tax selling concluding.


Taken over by the the end of the next one?

[inanaco] 04/4/2023 09:58

ISA £20k trades

[marcusl2] 04/4/2023 08:16

ADCs and Bispecifics are such a hot area. Scancell has 5 and more will be coming.



ADC plus Keytruda PD-1 combo bags FDA nod for urothelial cancer

[marcusl2] 03/4/2023 20:40

Hopefully Scib-1 plus PD-1 and then iScib does a lot better.

[marcusl2] 03/4/2023 15:30

Sitting on $15 billion, BioNTech has doled out $170 million upfront for the rights to two ADCs in development at China’s Duality Biologics.

BioNTech receives exclusive licenses from DualityBio for two investigational ADCs


DualityBio receives upfront payments totaling $170 million, and will be eligible to receive development, regulatory and commercial milestone payments potentially totaling over $1.5 billion as well as single-digit to double-digit tiered royalties

[marcusl2] 03/4/2023 15:25

The deal sees Takeda pay $5 million upfront and commit up to $410 million in development, regulatory and commercial milestones for the exclusive worldwide rights to develop ADCs using a panel of Innate antibodies against an undisclosed target. Takeda is responsible for all work to develop ADCs directed at the target with a primary focus on celiac disease.

[the real lozan] 03/4/2023 10:53

They set up this forum -
Why ???
A 'tedium' toss-up between interest here or being stuck at Dover.
Reading the posts here is like getting a 'postcard' from someone you didn't even know had gone away...to somewhere you have no intention of ever visiting.

[inanaco] 03/4/2023 07:49

Soon know ....

""We’ve had to go longer and deeper, but when we get there it will be a bigger story because we will have achieved what nobody else has achieved""

Tickets for 2023/24 ISA allowance on sale shortly ...

You can pre-buy and Transfer in, on and after the 6th April (buy before 5th)

Don't forget this is the last year of the £12000 capital gains tax allowance 22/23

Next year it drops by half to £6000 23/24

then disappears
if you have capital gains tax profits in Scancell and you want to include in 2022/23 tax year you can sell before the 5th April .. but you cant buy back for a min of 30 days in the same account otherwise the profit will be included in 23/24 tax year how ever you can sell and buy back into ISA without penalty

this is your last chance to fill your 2022/23 ISA tax allowance which expires on the 5th

IMHO

[marcusl2] 02/4/2023 14:17

ratcliffewriter

Strong Buy

Looking back at AGM commentsToday 10:32

I found the recordings from the AGM buried in my phone's downloads, so have transcribed a few bits (unedited, to avoid accusations of cherry picking) -
Lindy on Glycans - ‘By making antibodies to the sugars that are likely to be just on cancer we’re getting superb specificity – we’re one of the very few companies in the world that can make these high affinity IGG antibodies that are really good at doing this, and that’s basically what Genmab were so excited about and that’s why we got the deal with Genmab.
Each of those sugars could be on lots of different proteins, on lots of different glycolipids and that means they can have potentially different mechanisms of action, so you could have an antibody binded to a sugar on a protien that’s internalised, and that’s a great way of delivering drugs, specifically to the cancer, and that’s what Genmab are really excited about and going to take forward.'
On SCLC - 'Our antibody binds beautifully to that tumour and not to (so far) any normal tissue – So this could be - and I’m always cautious about this - the Holy Grail of a completely cancer-specific antibody, and that’s why we’re taking this one into the clinic ourselves.'
Shareholder question re Biontech – 'regarding the T cells they wanted from the Modify trial – are they still interested in that and are you able to harvest those cells at this point?'
LD reply - 'The simple answer is yes they’re still interested and yes we can harvest them – they’re doing that as we speak... They’re even more interested in the vaccine though because that’s a simpler and cheaper way forward, so if we continue to get good clinical data they would be definitely one of the companies that we would engage with.'

Just a bit to contemplate in the run up to whatever AACR brings - earth-shattering, routine, or somewhere in between - we will find out whether we get all excited or just sit and watch the calendar move along.

Again, word for word, and a very pertinent and enduring question for many of us - (The shareholder's first name was given by LD but it is not relevant here I don't think)
‘Why do you believe the stock market doesn’t believe the good news of our story, and is it that we don’t have strong enough PR into that area of the advertising stock market?'
Lindy - 'We do not have an approved cancer vaccine, so there is a lot of cynicism out there that cancer vaccines can actually work, so for instance the deal we’ve done with the antibodies wasn’t even for a product, it was for a target and it was a great deal because there’s lots of antibodies already approved, so people know what they’re looking for, they know how they’re going to work, they feel confident, and comfortable with that whole area. There are still a lot of scepticisms about the vaccine. So therefore we need to go further, and that we already know. We’re in the clinic now, good news. We’re recruiting, good news. We’re getting T cell responses – good news. But we need clinical responses as well. First patient’s looking good but we need more than one patient to convince people. It will be the flip side – if this really is working and looking good there will be huge enthusiasm. We’ve had to go longer and deeper, but when we get there it will be a bigger story because we will have achieved what nobody else has achieved and like everything when you’re the first it’s tougher. At that point maybe we need different or better or stronger PR and I think there’s lots of people – Simon and his team amongst them waiting for that moment to go out and shout about it, it’s just that little bit too soon. But soon - we’re getting there definitely, that’s the exciting bit.'
(Note - WHEN we get there it WILL l be a bigger story because we WILL have achieved what nobody else has achieved)

And finally, a comment which has been posted before but bears repeating, from Martin Diggle - (in his words wearing his shareholder’s hat as opposed to his board hat) ‘It’s fair to say we’ve been invested in over a dozen life science companies in the last decade, and this is probably the most exciting thing we’ve ever seen, so well done.’

thanks to Botski for making the recording...

[torquayfan] 02/4/2023 10:40

Marcus you can filter on LSE too ! No excuses now LOL

[marcusl2] 02/4/2023 08:50

I can filter people here ;-)

Really looking forward to Scancell`s update by 18th April. Fingers crossed for all the cancer patients who will benefit now and in the future from Modi-1, Modi-2 and more.

We are not a one-trick pony though. I expect Avidimab, the Glymabs and Immunobody to be huge assets as well.

Maybe Scancell will be taken over in 2024

Cash positions of Big Pharma

[torquayfan] 02/4/2023 01:29

Marcus thanks for that heads up earlier this week.

We had already heard of one Patient with H & N cancer doing very well and now possibly, there's another Modi 1 Patient with either with H & N or kidney cancer making progress, (although that report might be from a SCIB1 target or another trial) - that's two reports anyway that cancer vaccines could be working nicely.

I see no reason to panic about the raising of expectations - many of us already have expectations along with some optimism do we not?

And these heartfelt insights from the Patients are for me, good to see and no doubt they, the Patients, will on reflection, understand the interest here, given that we are invested in the Company that is providing this hope for them.

I hope we find more snippets of this nature and as the trials expand and progress, it seems inevitable we shall hear more.

It's gone quiet here. BTW an excellent discussion about the coming RNS and the AACR situation on LSE yesterday - I wonder why you don't post there too ? ATB

[marcusl2] 01/4/2023 16:26

Avidimab worked well with Covidity and will hopefully soon start with iScib when MHRA give the nod.

[marcusl2] 01/4/2023 12:37

(from 22nd - 24th of September, 2022 Hamburg)
PRESENTER
Bubacarr G Kaira
Unlocking the unique potential of AvidiMAb® in fighting cancer

Avidity, the combined binding strength of individual interactions, is a key aspect of cancer-targeting by therapeutic antibodies. Strategies to enhance antibody avidity prove valuable in the context of prolonged target occupancy and/or enhanced signalling,two critical pharmacodynamic factors..

Using scancell’s proprietary method we have generated a series of anti-glycan monoclonal antibodies (GlyMab®) with cancer therapy potential. These GlyMabs were subsequently avidity-enhanced leading to enhanced anti-tumour activity in
vivo, through our Fc-engineering AvidiMab® technology (1) . Briefly, the introduction of select residues from murine IgG3,an isotype known to exhibit cooperative binding, promoted non-covalent Fc:Fc associations by neighbouring target-bound mAbs. We next sought to expand the applicability of our avidity-promoting strategy by focusing on agonistic mAbs with cancer immunotherapy potential such anti-CD40 agonists (2).

CD40, a tumor necrosis factor receptor (TNFR) superfamily member, plays a critical role in B and T cell immunobiology. Agonistic CD40 mAbs act via mimicking CD40L-induced CD40 clustering and signalling thereby activating antigen presenting
cells (APC) and expanding cytotoxic T cells(3). The CD40 interaction of parental SEA-CD40 and avidity-enhanced SEA-CD40 (iSEA-CD40), was analysed using SPR and higher order complex formation via DLS. Cell-based proliferation and activation
assays were used to validate the observations. iSEA-CD40 displayed more avid CD40 binding and larger CD40 complex formation, in addition to exhibiting B cell superior proliferative capability, compared to SEA-CD40.

[marcusl2] 01/4/2023 12:26

The two Glymabs that will be out-licensed have both been engineered with Avidimab.

SC88 • Lewisacx • Colorectal cancer

AvidiMab TM technology introduces intermolecular cooperativity => enhanced target avidity

 AvidiMab TM-engineered SC88, i88G1, exhibits inflammatory cell killing (ICD) through pore formation

SC27 • Lewisy • Ovarian cancer

SC27 targets over 55% of colorectal, 86% gastric, 38% ovarian and 46% breast cancer tissues
 SC27 exhibits in vivo anti-tumour activity

 AvidiMab TM engineered SC27, i27G1 exhibits improved functional affinity and direct cell killing



SC88 is in lead candidate selection and targets Lewisacx with a view to addressing colorectal cancer. The cell-based studies again showed highly specific target binding with little off-target effects.

SC27 is in functional analysis targeting Lewisy for gastric cancers. Preclinical studies have shown it to be more selective and potent than previous Lewisy targeting approaches.

[pharmaboy3] 31/3/2023 19:32

Wouldn't it be nice if we announced something to coincide with ....HTTps://www.linkedin.com/posts/isa-pharmaceuticals_isa-isa101b-oralcancer-activity-7047510171903811584-FDCr?utm_source=share&utm_medium=member_android

[marcusl2] 31/3/2023 09:35

Discover our Cancer Vaccine AACR Pre-Conference Planner 2023! Our analyst team have saved you valuable time, as they have screened and identified 50 Cancer Vaccine-relevant abstracts, including 18 clinical and 32 preclinical. Download here -


Dr Lennard Lee (Oxford University)
@drlennardlee

Research in #cancervaccine continues to accelerate 🚗At the #AACR23 international conference there were 50 reports, 18 which are clinica 👨‍⚕;️l. #cancervaccines are going to land sooner than we think ✈️. I’m excited. Looking forwards to the UK advances here.